# Xellar Biosystems

> Xellar Biosystems combines microfluidic human organ models, laboratory automation, high-content imaging and AI to support drug discovery, efficacy testing and safety assessment. Its OC-Plex platform and research services serve biopharmaceutical researchers seeking human-relevant experimental data.

- **Founded:** 2022
- **Headquarters:** Boston, United States
- **Founders:** Xin Xie (Cofounder and CEO), Hermione He (Cofounder; Strategy & Investor Relations)
- **Products:** OC-Plex, E.P.I.C. Platform, Efficacy and toxicity models, Custom R&D, Personalized medicine research
- **Notable:** OC-Plex 8/32 received a 2024 Q2 Product Award in HealthTech., Peer-reviewed thermoplastic microfluidic prototyping research first published in November 2023., Published liver-chip proof of concept tested 17 compounds; the abstract reports 85.7% sensitivity, 100% specificity and 92.3% accuracy in its stated evaluation.

## Products & services

- **OC-Plex** — Commercial microfluidic organ-chip platform for dynamic 3D human cell culture, tissue interactions and drug-response studies.
- **E.P.I.C. Platform** — Integrated engineering, preclinical modeling, high-content imaging and AI computation workflow.
- **Efficacy and toxicity models** — Tumor, vascular, liver-injury and kidney models for research and drug testing.
- **Custom R&D** — Organ-on-chip research services designed around fit-for-purpose throughput and biological complexity.
- **Personalized medicine research** — Patient-derived tumor models for functional drug-response testing.

## Achievements

- OC-Plex 8/32 received a 2024 Q2 Product Award in HealthTech.
- Peer-reviewed thermoplastic microfluidic prototyping research first published in November 2023.
- Published liver-chip proof of concept tested 17 compounds; the abstract reports 85.7% sensitivity, 100% specificity and 92.3% accuracy in its stated evaluation.
- Cancer-chip research published online in February 2026 integrates deep-learning-based image translation with drug-response testing.

## Latest updates

- **2026-06** — Announced US$50 million in combined Series A and A+ financing for automation, AI/computational biology and virtual-cell development.
- **2026-02** — Cancer organ-chip and deep-learning study published online in Advanced Science.
- **2025-12** — Liver-on-chip predictive safety assessment study published online in Toxicology.

## Links

- Website: https://xellarbio.com/
- LinkedIn: https://www.linkedin.com/company/xellar-biosystems/
- Twitter/X: https://twitter.com/XellarBio

---

Profile page: https://yespress.io/xellar-biosystems
Published by YesPress — https://yespress.io
Last updated: 2026-10-05